J&J's ketamine-derived nasal spray approved by FDA to treat …
1 day ago · The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. …
FDA approves standalone use of J&J’s ketamine-derived ... - CNN
1 day ago · The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe …
FDA approves Johnson & Johnson’s ketamine-derived nasal …
M ajor depressive disorder affects an estimated 8.3% of the adult population. And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to give rapid relief to ...
FDA approves Johnson & Johnson’s ketamine-derived nasal …
4 hours ago · FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment. Beth Greenfield. Thu, January 23, 2025 at 1:28 AM UTC. 2 min read.
Ketamine Nasal Spray Approved as Standalone Treatment for …
6 hours ago · This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that …
J&J's ketamine-derived nasal spray approved by FDA to treat …
1 day ago · The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. …
Johnson & Johnson ketamine-derived nasal spray gets FDA …
10 hours ago · Johnson & Johnson beat analyst expectations for revenue by $70 million, but highlighted possible negative impacts in its outlook from an ongoing talc lawsuit and slower …
FDA approves Johnson & Johnson nasal spray Spravato for …
1 day ago · Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
US FDA approves J&J's ketamine-based therapy to treat …
(Reuters) -The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with major depressive disorder, the company said …
FDA Approves Johnson & Johnson’s Ketamine-Derived Drug For ... - Forbes
Mar 6, 2019 · The U.S. Food & Drug Administration Tuesday approved Johnson & Johnson’s ketamine-derived nasal spray Spravato for treatment-resistant depression.
- Some results have been removed